3 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Rene Kahn: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| European Long-acting Antipsychotics in Schizophrenia Trial-II Schizophrenia | Completed | Rene Kahn | 159 | 2021-12-31 | 2026-11-10 | |
| Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe Omega-3 fatty acids, Placebo - Ultra High Risk for Psychosis | Phase 4 | Completed | Rene Kahn | 146 | 2016-09-30 | 2026-11-17 |
| Optimization of Treatment and Management of Schizophrenia in Europe Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment - Schizophrenia, Schizophreniform Disorder | Phase 4 | Completed | Rene Kahn | 479 | 2011-05-01 | 2018-05-15 |
Psychotic Disorders (2) · Schizophrenia (2)
Fatty Acids, Omega-3 (1) · Psychosocial Intervention (1)
Israel (3) · Austria (2) · Germany (2) · Italy (2) · Netherlands (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · France (1) · Norway (1)
PMID 30115598, PMID 33536130, PMID 33838518, PMID 36988483, PMID 39450759
2015 (1)